Sunlight to feed the world 20/04/2021 Merck Photonics is an industry that has aroused Merck's curiosity for more than 30 years Partners - Merck
Sharing -not competing- in the fight against Covid-19 19/04/2021 Merck is accelerating development and production, and bringing resources and expertise to help identify effective and... Partners
ORYZON receives the INNOVATIVE SME seal from the Ministry of Science and Innovation 19/04/2021 Oryzon Genomics Innovation present in Oryzon's programs in the field of epigenetics acknowledged. The company currently has 2 compounds... Partners - Oryzon Genomics
MDR Literature Search 15/04/2021 AKRN Scientific Consulting This article will focus on the Systematic Scientific Literature Search and Review as part of the Clinical Evaluation... Partners - AKRN Scientific Consulting
The National Spanish Hospital of Paraplegics and Merck collaborate in an international res... 14/04/2021 This collaboration responds to the high quality of the research and scientific talent of the Hospital Nacional de... Partners
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and Lic... 13/04/2021 Ysios Capital Partners Mirum expands potential opportunities across rare disease pipeline and Vivet will lead pre-clinical development of its... Partners - Ysios Capital Partners
Using cardio-metabolomic diagnosis to reduce the consequences of obesity 07/04/2021 Biotech company OWL Metabolomics develops non-invasive, early diagnosis products for obesity-related diseases Partners
ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount ... 06/04/2021 Oryzon Genomics Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models Partners - Oryzon Genomics
Our researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant 31/03/2021 Laminar Pharma In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after a successful 15-year... Partners - Laminar Pharma
ORYZON enrolls first patient in PORTICO 29/03/2021 Oryzon Genomics PORTICO is a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder recruiting patients in Europe... Partners - Oryzon Genomics